Guideline Recommendations for Streptococcal Pharyngitis Treatment

First‑Line Antibiotic Therapy

• Penicillin or amoxicillin administered for 10 days is the definitive first‑line treatment for acute group A streptococcal (GAS) pharyngitis, with no documented penicillin‑resistant GAS strains. [1][2]
• Amoxicillin 50 mg/kg once daily (maximum 1000 mg) for 10 days is preferred because once‑daily dosing improves adherence while providing efficacy equivalent to penicillin V. 2
• Penicillin V at standard dosing (≈250 mg twice or three times daily in children, 500 mg twice daily in adults) for 10 days remains an excellent oral option. [1][2]
• Benzathine penicillin G given as a single intramuscular injection (600,000 IU for children < 27 kg; 1,200,000 IU for larger children and adults) is appropriate when oral adherence is uncertain. 1

Duration and Resistance Considerations

• A full 10‑day course is critical for maximal pharyngeal eradication of GAS and for preventing acute rheumatic fever, despite the infection’s self‑limited nature. [1][2]
• Penicillin remains the treatment of choice because of its proven efficacy, narrow spectrum, low cost, and the complete absence of penicillin‑resistant GAS isolates. [1][2]

Management of Penicillin‑Allergic Patients

Non‑Anaphylactic Allergy (e.g., rash)

• First‑generation cephalosporins for 10 days are acceptable alternatives. 2

Anaphylactic or Severe Penicillin Allergy

• Clindamycin 7 mg/kg three times daily (maximum 300 mg per dose) for 10 days in children; 300 mg three times daily in adults for 10 days provides effective coverage of GAS. 2
• Azithromycin 12 mg/kg once daily (maximum 500 mg) for 5 days in children; 500 mg once daily in adults is an alternative, but clinicians must consider regional macrolide resistance. 2
• Macrolide (azithromycin, clarithromycin) resistance in GAS ranges from 5 % to 8 % in most U.S. regions and can be substantially higher in certain locales, potentially leading to treatment failure. 2
• Clarithromycin 7.5 mg/kg twice daily (maximum 250 mg per dose) for 10 days in children; 250 mg twice daily in adults is another alternative, subject to the same resistance concerns. 2

Expected Clinical Course and Monitoring

• Symptomatic improvement (reduction of sore throat, fever) typically occurs within 24–48 hours after initiating antibiotic therapy. 2
• Treatment of GAS pharyngitis prevents acute rheumatic fever, suppurative complications (e.g., peritonsillar abscess, cervical lymphadenitis), and reduces transmission to contacts. [1][2]

Follow‑Up and Post‑Treatment Testing

• Routine post‑treatment throat cultures or rapid antigen detection tests are unnecessary after completing a full antibiotic course. 2
• Asymptomatic household contacts do not require testing or empiric antibiotic prophylaxis, as prophylaxis has not demonstrated a reduction in subsequent GAS pharyngitis and carries risks of adverse effects and resistance. 2

Avoidance of Aspirin in the Management of Group A Streptococcal Infection in Older Adults

Adjunctive Analgesic Therapy

• Aspirin should not be used for pain or fever in geriatric patients with GAS infection because it increases bleeding risk and does not provide superior symptom relief compared with other analgesics such as NSAIDs or acetaminophen. 3

Guideline Recommendations for Antibiotic Management of Streptococcal Pharyngitis and Tonsillitis

First‑Line Therapy

• Penicillin V or amoxicillin for 10 days remains the gold‑standard treatment because it has proven efficacy in preventing acute rheumatic fever, a narrow antimicrobial spectrum, no documented resistance in Group A Streptococcus, excellent safety, and low cost (IDSA guideline – strong recommendation). 4

Alternatives When Penicillin Cannot Be Used

Non‑Anaphylactic Penicillin Allergy (e.g., rash, hives)

• First‑generation cephalosporins (e.g., cephalexin, cefadroxil) are preferred over cefixime; they have stronger guideline endorsement and a low cross‑reactivity risk of approximately 10 % (IDSA guideline – moderate recommendation). 4

Anaphylactic or Severe Immediate‑Type Penicillin Allergy

• All cephalosporins, including cefixime, must be avoided because of the risk of cross‑reactivity (IDSA guideline – strong recommendation). 4
• Clindamycin is the most reliable alternative, with only about 1 % Group A Streptococcus resistance reported in the United States (IDSA guideline – moderate recommendation). 4
• Azithromycin is an acceptable alternative, but macrolide resistance ranges from 5 %–8 % nationally and can be substantially higher in some regions, increasing the risk of treatment failure (IDSA guideline – moderate recommendation). 4

Use of Cefixime

• Cefixime may be used only when penicillin, amoxicillin, and first‑generation cephalosporins are unsuitable, such as in patients with a non‑anaphylactic penicillin allergy who cannot tolerate first‑generation agents (IDSA guideline – conditional recommendation). 4

Avoidance and Pitfalls

• Do not prescribe cefixime as a first‑line agent when penicillin or amoxicillin are viable options; the lack of data demonstrating rheumatic fever prevention makes cefixime inferior despite FDA approval (IDSA guideline – strong recommendation). 4
• Do not shorten the cefixime course below 10 days; the FDA label specifies a minimum therapeutic duration of 10 days for streptococcal infections (IDSA guideline – strong recommendation). 4
• Do not avoid first‑generation cephalosporins in patients with non‑anaphylactic penicillin allergies; IDSA guidelines explicitly endorse their use, favoring cephalexin or cefadroxil over cefixime (IDSA guideline – strong recommendation). 4
• Do not prescribe cefixime for patients with anaphylactic penicillin reactions; all cephalosporins must be avoided due to cross‑reactivity concerns (IDSA guideline – strong recommendation). 4

Adjunctive Symptomatic Management

• Aspirin should be avoided in children because of the established risk of Reye syndrome (IDSA guideline – strong recommendation). 4
• Systemic corticosteroids are not recommended for routine use in streptococcal pharyngitis; they provide only minimal symptom reduction and are not endorsed by IDSA guidelines (IDSA guideline – weak recommendation). 4

Guideline Recommendations for Managing Asymptomatic Household Contacts in Recurrent Group A Streptococcal Pharyngitis

Recommendation Overview

• The Infectious Diseases Society of America (IDSA) recommends against routine diagnostic testing or empiric treatment of asymptomatic household contacts, including sexual partners, for adults with recurrent streptococcal pharyngitis (strong recommendation, moderate‑quality evidence) 5.

Rationale

• Testing an asymptomatic partner does not clarify whether recurrent episodes represent multiple true GAS infections or chronic pharyngeal carriage with superimposed viral infections 5.

Clinical Algorithm

• No temporal link to sexual contact – Do not test the partner; instead, verify that each symptomatic episode in the patient is a true GAS infection by performing a rapid antigen detection test (RADT) or throat culture during symptomatic periods 5.
• Partner is symptomatic – Test and treat the partner based on their own clinical presentation rather than as a contact‑screening measure 5.

Common Pitfalls to Avoid

• Reflex testing/treatment of asymptomatic partners – This practice contravenes guideline recommendations and contributes to unnecessary antibiotic exposure and resistance development 5.
• Confusing Group A Streptococcus with Group B Streptococcus – Unlike GBS, routine partner screening for GAS is unwarranted except in rare, clearly documented sexual‑transmission scenarios 5.
• Post‑treatment cultures – Performing throat cultures after completing an appropriate 10‑day course of penicillin or amoxicillin is not routinely indicated for either the patient or the partner 5.

When to Reconsider the Diagnosis

• If an adult patient continues to experience “recurrent strep throat” despite adequate antibiotic therapy, consider chronic GAS carriage with repeated viral pharyngitis; positive RADTs or cultures during symptomatic episodes likely reflect carriage rather than active infection, rendering partner testing unhelpful 5.